PulmVita

PulmVita, led by Cole Christianson and Dr. Andrew Martin, is developing a new nasal cannula device that can be used with existing portable oxygen concentrators, providing several advantages to patients, which most notable include an efficient, portable, and reliable exposure to oxygen during low activity times (e.g., sleeping). By doing so, PulmVita’s interface empowers oxygen users to travel more freely and rely on a single and portable source of oxygen.

Since joining the program, PulmVita has:

• Incorporated the company;

• Created value proposition canvases;

• Identified the total attainable market;

• Identified the competition in the space and carved a niche;

• Developed valuation scenarios;

• Positioned itself to raise $1M.